At the SIO congress in Palermo, specialists flagged short real-world adherence and no national reimbursement in Italy. Oral semaglutide and orforglipron are expected there in 2027.
Recap by typeshit. Full story at Il Sole 24 ORE.
A short clip from Dr. Reese pushing back on the rush toward peptides as an easy shortcut, with little detail beyond that.
11:54
Ryan Sims of Optimal Health Project gives a follow-up on how things have gone in the months since his 35-pound loss on the experimental drug.
The Tico Times reports Costa Rica's public system is considering offering GLP-1 weight loss drugs to patients. Tap through for where the discussion stands.
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
Researchers are studying whether GLP-1 drugs, which act on mood, appetite and reward pathways, could help with depression, addiction and binge eating.
A retrospective cohort checks whether retinal disease started or worsened more in established users than in people never on either drug, plus a regional NAION review.
Loading…